Introduction: Although the prevalence and burden of asthma are continuously increasing, there is a lack of evidence on the landscape of moderate-to-severe asthma in Japan. Here, we report the prevalence of moderate-to-severe asthma and describe patient’s demographics and clinical characteristics from 2010 to 2019 using the JMDC claims database. Methods: Patients (≥12 years) from the JMDC database with ≥2 asthma diagnoses in 2 different months in each index year were stratified as moderate-to-severe asthma based on the definition of asthma prevention and management guideline (Japanese Guidelines for Asthma, JGL) or Global Initiative for Asthma (GINA). Primary objective: 10-year trend (2010–2019) in the prevalence of moderate-to-severe asthma. Secondary objective: Demographics and clinical characteristics of patients from 2010 to 2019. Results: Of 7,493,027 patients from the JMDC database, 38,089 and 133,557 were included in JGL and GINA cohorts, respectively, by 2019. Both cohorts presented an increasing trend in the prevalence rate of moderate-to-severe asthma from 2010 to 2019, irrespective of age groups. Demographics and clinical characteristics were consistent across the cohorts in each calendar year. Majority of patients were in the age group of 18–60 years in both JGL (86.6%) and GINA (84.2%) cohorts. Allergic rhinitis was the most frequent comorbidity and anaphylaxis the least frequent comorbidity reported in both the cohorts. Conclusions: In Japan, the prevalence rate of patients with moderate-to-severe asthma, as per JGL or GINA in the JMDC database, increased from 2010 to 2019. The demographics and clinical characteristics were similar in both cohorts over the assessment duration.

1.
Sato K, Ohno T, Ishii T, Ito C, Kaise T. The prevalence, characteristics, and patient burden of severe asthma determined by using a Japan health care claims database. Clin Ther. 2019;41(11):2239–51.
2.
GBD 2019 Diseases and Injuries Collaborators; Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.
3.
Adachi M, Hozawa S, Nishikawa M, Yoshida A, Jinnai T, Tamura G. Asthma control and quality of life in a real-life setting: a cross-sectional study of adult asthma patients in Japan (ACQUIRE-2). J Asthma. 2019;56(9):1016–25.
4.
Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int. 2014;111(50):847–55.
5.
Tamaoki J. Asthma prevention and management guideline 2018. Arerugi. 2018;67(9):1263–8.
6.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2020. Available from: https://ginasthma.org. Accessed on 3 March 2021.
7.
Ohta K, Minoguchi K, Mizuno H, Oyama N. Current status of asthma therapy in Japan and patient satisfaction: actual–II: a Clinical survey to Understand real Asthma Life for patients–II. Allergology Immunol. 2010;17:2046–54.
8.
Inoue H, Milligan KL, McConnon A, Yoshisue H, Loefroth E, McSharry M, et al. Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA. NPJ Prim Care Respir Med. 2021;31(1):12.
9.
Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019;29(1):13–7.
10.
Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53–60.
11.
Sato K, Ishii T, Kaise T. Burden of asthma in elderly Japanese patients: using hospital-based administrative claims data. Pulm Ther. 2020;6(2):247–60.
12.
Sobue T, Fukuda H, Matsumoto T, Lee B, Ito S, Iwata S. The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan. PLoS One. 2021;16(8):e0256379.
13.
Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–9.
14.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
15.
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246.
16.
Yang F, Busby J, Heaney LG, Menzies-Gow A, Pfeffer PE, Jackson DJ, et al. Factors associated with frequent exacerbations in the UK severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7):2691–701.e1.
17.
Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69(3):331–45.
18.
Nakamura Y, Tamaoki J, Nagase H, Yamaguchi M, Horiguchi T, Hozawa S, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69(4):519–48.
You do not currently have access to this content.